Milestone Pharmaceuticals Inc (MIST) Dividends

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.